---
schema_version: "secwatch.filing_event.v1"
accession: "0001824293-26-000009"
form_type: "8-K"
ticker: "GRI"
cik: "0001824293"
company_name: "GRI Bio, Inc."
filed_at: "2026-01-15T23:59:59+00:00"
generated_at: "2026-05-16T10:12:09.313937+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# GRI Bio shareholders approve reverse stock split; company addresses Nasdaq equity deficiency with $8M offering

## Summary
- Shareholders approved reverse stock split at ratio between 1:2 and 1:30, with board discretion to set exact ratio or abandon.
- Company received Nasdaq deficiency notice on Nov 26, 2025 for stockholders' equity below $2.5M.
- Dec 12, 2025 public offering raised ~$8.0M gross proceeds, bringing equity above the $2.5M minimum.
- Nasdaq will monitor compliance at next periodic report; failure may lead to delisting.

## SEC filing metadata
- accession: 0001824293-26-000009
- form_type: 8-K
- ticker: GRI
- cik: 0001824293
- company_name: GRI Bio, Inc.
- filed_at: 2026-01-15T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.07, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824293/000182429326000009/0001824293-26-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824293/000182429326000009/val-20260115.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001824293-26-000009
- JSON: https://secwatch.observer/filing/0001824293-26-000009.json
- Plain text: https://secwatch.observer/filing/0001824293-26-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.